Category: Local

Genentech’s Alecensa (Alectinib) Phase III Results

South San Francisco, CA   June 5, 2017  Genentech Press Release   Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type…